What smart money is saying about Thermo Fisher Scientific
TMO · Healthcare · Medical - Diagnostics & Research · Market cap $250.15B
10 funds in our archive have pitched Thermo Fisher Scientific, most recently Broyhill Equity Composite in September 2026.
Company profile
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
Get an email when a fund buys, sells or pitches it
Fund signal · last 12 months
60 lettersFunds are split between buying and selling
0
Net flow
11 buys · 5 new positions · 50%11 sells · 7 full exits
Moves described in fund letters in our archive. A sentence published word for word by several funds of one house in the same quarter counts once.
Position history
Between Q4 2024 and Q3 2026, 63 fund letters reported a position in Thermo Fisher Scientific, with 12 buys (opened or added) and 11 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 41 | 2 | 7 | 5 |
| Q2 2026 | 16 | 8 | 4 | 0 |
| Q4 2025 | 3 | 1 | 0 | 1 |
| Q3 2025 | 2 | 1 | 0 | 1 |
| Q2 2025 | 1 | 0 | 0 | 2 |
| Q4 2024 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 63 positions · 25 moves
- September 2026
“Thermo Fisher Scientific (+35%) was the portfolio’s largest contributor during the quarter, following strong second- quarter results.”
Thermo Fisher Scientific - September 2026
“Top contributors to relative performance: In IT, new holding Lenovo reported quarterly results that significantly exceeded expectations. Revenue in its infrastructure business nearly doubled as large customers, including cloud-computing providers, increased spending on AI servers and related equipment. After memory-chip stocks tumbled, the portfolio purchased SK hynix, benefiting from a subsequent partial rebound in its shares amid evidence of continued strong demand for high-bandwidth memory used in AI servers. Software and services holdings Accenture, Adobe, and SAP outperformed as investors’ fears over AI-related disruption eased. In Consumer Discretionary, Japan-based Sony reported better-than-expected earnings as gaming price increases offset rising memory costs and demand for smartphone image sensors stayed strong. In Communication Services, Meta Platforms’ new personal AI assistant, Muse, quickly rose to the top of Apple’s App Store in September, reinforcing investor optimism about the company’s position in consumer AI services. Selection Effect Allocation Effect Total Effect 2.1Total Effect: 2.2Selection Effect: -0.1Allocation Effect: -1.0 0.0 1.0 2.0 Effect (%) Selection Effect Allocation Effect Total Effect 2.1Total Effect: 2.3Selection Effect: -0.2Allocation Effect: RegionSector Third Quarter 2026 Performance Attribution Global Equity Composite vs. MSCI ACWI Index Selection Effect Allocation Effect Total Effect Top detractors from relative performance: The portfolio’s large overweight in Industrials hurt relative returns. Battery leader CATL underperformed amid challenges in its local market. Chinese EV production has disappointed this year, and there are concerns about slower domestic growth for energy-storage systems as Chinese subsidies are phased out. Also in Industrials, higher oil prices weighed on aerospace-parts supplier HEICO and airline Ryanair. The portfolio was modestly underweight the best-performing sector, Energy, which detracted from relative returns. 7Global Equity Third Quarter 2026 Report Portfolio Attribution by Region Strong US holdings across a variety of industries more than offset weak picks in the EMU region. Top contributors to relative performance: In the US, improved funding conditions for biopharmaceutical research benefited life-sciences tools manufacturer Thermo Fisher Scientific.”
Thermo Fisher Scientific - September 2026
“On an individual stock basis, the largest contributors to relative returns were Thermo Fisher Scientific and not owning Applied Materials, KLA, Lam Research and Caterpillar.”
Thermo Fisher Scientific - September 2026
“In addition to the transactions discussed above, we initiated a new position in Danaher in the health care sector. We exited positions in Thermo Fisher Scientific, Gilead Sciences and Elanco Animal Health in the health care sector, Broadcom in the IT sector, Nestle and Celsius in the consumer staples sector, GXO Logistics and WESCO International in the industrials sector and Teck Resources in the materials sector.”
Thermo Fisher Scientific - September 2026
“Outside of AI, Thermo Fisher Scientific and Airbnb were also positive contributors.”
Thermo Fisher Scientific - September 2026
“Thermo Fisher Volumes are turning, and AI companies could become new customers At Morgan Stanley's 24th Annual Global Healthcare Conference on 15 September, the picture was strengthened that Thermo Fisher's underlying markets are on their way to recovering, which in practice means rising volumes. For a company like Thermo Fisher, higher volumes usually give clear operating leverage in earnings. Over the past 25 years, operating profit has grown about 4 percentage points faster than revenue per year (median). In addition to the cyclical recovery, a new customer group is emerging. Large investments are being made in automated laboratories and AI-based drug discovery, backed by technology companies, AI players and well- funded investors. This broadens the customer base to players with considerably greater financial resources than the traditional research market. Thermo Fisher is well positioned for this development. AI can generate hypotheses, but the results still have to be tested physically, and automated laboratories increase the need for instruments, analyses and consumables. Regardless of who drives the development, the business rests on the same underlying infrastructure. As the market's broadest supplier, Thermo Fisher has both the scale and the customer relationships to benefit from increased investment activity. Danaher, which is also held by the fund, has exposure to the same driver. The effect does not stop at early-stage research. If more drug projects move on to clinical trials and commercial production, demand also increases in the company's other businesses, not least contract manufacturing. In addition, there is a still unproven opportunity to use the large installed base of instruments to sell software and data that complement the hardware. Since the holding was added in May, Thermo Fisher has been one of the fund's strongest contributors.”
Thermo Fisher Scientific - September 2026
“More positively, there was very little thematic consistency among the companies that performed well. B3, the operator of Brazil’s stock exchange, life-science tools company Thermo Fisher, and software and networking businesses Samsara and Cloudflare all made positive contributions.”
Thermo Fisher Scientific - September 2026
“ In the US, improved funding conditions for biopharmaceutical research benefited life-sciences tools manufacturer Thermo Fisher Scientific.”
Thermo Fisher Scientific - New positionDiamond Hill Large Cap Concentrated ETFSeptember 2026
“• Health care tools and diagnostics company Thermo Fisher Scientific is benefiting from recovering end-market demand following a multiyear slowdown after the pandemic.”
Thermo Fisher Scientific - September 2026
“Thermo Fisher Scientific Inc. is a global life sciences company offering analytical instruments, laboratory products, biopharmaceutical services, and specialty diagnostics. Shares rose on better-than-expected second-quarter results. Organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance to the top of its prior range, driven by improving pharmaceutical and biotechnology spending. Bioproduction remained a standout franchise, while the divestiture of the lower-quality microbiology business funded additional share repurchases. We retain conviction that the life sciences tools industry can return to growth approximately two percentage points above GDP and believe Thermo Fisher’s scale, disciplined capital allocation, and broad-based margin expansion position the company to lead the recovery.”
Thermo Fisher Scientific - HoldsNexus Investment Management ULCSeptember 2026
“Microsoft and Meta Platforms led the way, along with our healthcare holdings Thermo Fisher, Gilead and Pfizer.”
Thermo Fisher Scientific - September 2026
“Shares of health care tools and diagnostics company Thermo Fisher Scientific outperformed following strong second quarter results and improving customer activity across key life sciences end markets, reinforcing confidence in continued demand recovery.”
Thermo Fisher Scientific - September 2026
“Thermo Fisher added about 210 basis points, more than half of it in July.”
Thermo Fisher Scientific - TrimmedMatrix Asset AdvisorsSeptember 2026
“We trimmed positions in Amgen, Goldman Sachs, and Thermo Fisher Scientific on price strength.”
Thermo Fisher Scientific - September 2026
Listed in Tributary Capital Management Multi-Cap Core Equity Strategy’s reported holdings.
Thermo Fisher Scientific - September 2026
“Thermo Fisher Scientific was eliminated following a period of outperformance as it returned to historical valuation levels following signs of improvement in its end markets.”
Thermo Fisher Scientific - September 2026
“Portfolio Attribution by Region Strong US holdings across a variety of industries more than offset weak picks in the EMU region. Top contributors to relative performance: In the US, improved funding conditions for biopharmaceutical research benefited life-sciences tools manufacturer Thermo Fisher Scientific.”
Thermo Fisher Scientific - September 2026
“Cloudflare also fared well as investors continued to recognise the company’s role in edge computing, data security and the delivery of AI-enabled applications. 3 Thermo Fisher Scientific contributed strongly on an improvement in sentiment towards life-science tools and expectations for a more stable demand environment.”
Thermo Fisher Scientific - September 2026
“Thermo Fisher Scientific contributed strongly on an improvement in sentiment towards life-science tools and expectations for a more stable demand environment.”
Thermo Fisher Scientific - September 2026
“Thermo Fisher Scientific Inc. (TMO): TMO is a leading manufacturer of laboratory instruments, equipment, supplies and consumables for use in pharmaceutical research and development, pharmaceutical production, academic research, diagnostic labs, hospitals, clinics, etc. This is a highly diversified company participating in a very broad category. The company manufactures around 800,000 different products for sale to approximately 400,000 worldwide customers. Essentially, everything you could need in a laboratory setting from a glass beaker costing several dollars to a high precision electron microscope. After re-entering the stock at approximately $470-480 earlier this year, the stock has made a sharp valuation shift after multiple solid quarterly results. We exited our position above $600 on average.”
Thermo Fisher Scientific - September 2026
“Thermo Fisher Scientific (+35%) was the portfolio’s largest contributor during the quarter, following strong second- quarter results.”
Thermo Fisher Scientific - September 2026
“Thermo Fisher Scientific (+35%) was the portfolio’s largest contributor during the quarter, following strong second- quarter results.”
Thermo Fisher Scientific - September 2026
“Thermo Fisher Scientific (+35%) was the portfolio’s largest contributor during the quarter, following strong second- quarter results.”
Thermo Fisher Scientific - September 2026
“Thermo Fisher Scientific (+35%) was the portfolio’s largest contributor during the quarter, following strong second- quarter results.”
Thermo Fisher Scientific - September 2026
“Thermo Fisher Scientific (+35%) was the portfolio’s largest contributor during the quarter, following strong second- quarter results.”
Thermo Fisher Scientific - September 2026
“Thermo Fisher Scientific (+35%) was the portfolio’s largest contributor during the quarter, following strong second- quarter results. The global life-sciences tools and diagnostics company is held under our Enabling innovation in healthcare theme.”
Thermo Fisher Scientific - September 2026
“Life science bellwethers Thermo Fisher Scientific and Danaher helped pace the Fund’s strong quarterly returns. Investor sentiment improved alongside solid company results and brightening organic growth outlooks. Valuations are not stretched, in our view, and we still hold large positions in both stocks.”
Thermo Fisher Scientific - September 2026
“In life sciences, both Thermo Fisher and Danaher generated strong contributions, thanks to solid operating results and improving investor sentiment in the space.”
Thermo Fisher Scientific - September 2026
“Notable 3Q Contributors Thermo Fisher Scientific, Danaher, and LabCorp finished among the top quarterly contributors, as the Fund’s health care stocks delivered very strong returns.”
Thermo Fisher Scientific - September 2026
“Even better was the 35% share price increase from Thermo Fisher.”
Thermo Fisher Scientific - September 2026
Listed in Liontrust Global Dividend Fund’s reported holdings.
Thermo Fisher Scientific - September 2026
“To fund this buying we sold several of the healthcare, consumer and industrial franchises added in June, Lonza, Thermo Fisher, HEICO and Costco among them.”
Thermo Fisher Scientific - September 2026
“To fund this buying we sold several of the healthcare, consumer and industrial franchises added in June, Lonza, Thermo Fisher, HEICO and Costco among them.”
Thermo Fisher Scientific - September 2026
“The Compounding Capital pool is well diversified across businesses in industries enjoying positive tailwinds, such as live entertainment and sports content (e.g. Liberty Media (FWONK) owner of Formula One and MotoGP), Life Sciences (e.g. Thermo Fisher (TMO)), Semiconductors (e.g. Taiwan Semiconductor Manufacturing Co (2330)) and US Industrial activity (e.g. RB Global (RBA)).”
Thermo Fisher Scientific - TrimmedBuffalo Growth FundSeptember 2026
“The Life sciences picks and shovels provider Thermo Fisher Scientific had a standout quarter gaining 27% and was among the top contributors to fund performance. The life science tool space has been in flux since COVID, but we believe it has finally turned a corner with some stabilization in both China and their Academic/Gov’t end markets. Pharmaceutical and Biotech spending has begun to pick up as biotech funding has broadly improved as the much-anticipated pharmaceutical patent cliff looms. We trimmed the investment position following the strong run, but plan to continue to hold the balance as we see the setup improving from here.”
Thermo Fisher Scientific - ExitedFairtree Asset Management Global Equity FundSeptember 2026
“On the sell side, the largest reduction was to Microsoft, alongside trims to Fortinet, Evolution and Salesforce, while the Fund fully exited Thermo Fisher, S&P Global, Capgemini, Bid Corp and Zoetis, where the risk-reward or portfolio fit had become less compelling.”
Thermo Fisher Scientific - August 2026
Listed in Guinness Global Innovators Fund’s reported holdings.
Thermo Fisher Scientific - July 2026
“Danaher: A minor disappointment in Biotechnology but improving underlying markets Danaher also reported its second-quarter results during the month. The report beat market expectations on both revenue and earnings per share. The disappointment lay instead in the performance of the company's most important segment, Biotechnology, which came in below expectations, sending the Danaher share down by more than 15% during the day. The dominant explanation is that a couple of larger orders for major customers, scheduled for delivery in the second and third quarters, are instead being pushed into 2027 as a result of facility and scheduling issues at those customers. As a result, Danaher lowered its full-year guidance. Since the growth narrative sits within Biotechnology, which also carries higher profitability than the group as a whole, the impact is amplified. Underlying order intake for Biotechnology nevertheless remained strong, growing by around 15% for both equipment and key consumables. This is the second consecutive quarter of rapid order growth. The positive trend in Bioprocessing was also confirmed by Thermo Fisher, which said that the improved customer activity in biotech is now beginning to translate into actual revenue, and which raised its full-year guidance. A further data point supporting this thesis came recently from US-based Repligen, whose business consists 100% of Bioprocessing (equipment and consumables). As the fund has noted previously, the company often serves as a good indicator, since its order intake is a pure measure of Danaher's and Thermo Fisher's most important growth engine. During the second quarter, book-to-bill improved sharply sequentially and was said to be clearly above 1.0x, while the order book is being built up ahead of 2027. Order trends are strong overall, and China has improved markedly (+60% in the first half), accounting for 8–10% of Thermo's and Danaher's respective revenue. There is also growing discussion around reshoring production. Repligen has won several large capacity expansion projects and, according to the company, is “on track to win a third within the coming weeks”, which confirms that this investment cycle is also under way. The fund increased its holding in Danaher on the day of the report, as the share price decline was judged to be excessive. Danaher and Thermo Fisher account for 5.2% and 4% respectively of Kavaljer Investmentbolagsfond”
Thermo Fisher Scientific - July 2026
Listed in WS Lindsell Train North American Equity Fund’s reported holdings.
Thermo Fisher Scientific - July 2026
“Thermo Fisher (+12%) and Prada (+7%) both delivered pleasing results, largely outperforming their peers in the Life Sciences and Luxury sectors respectively.”
Thermo Fisher Scientific - July 2026
“Stock selection remained strong across several structural growth themes. Notable contributors included BayCurrent, Thermo Fisher, Expedia, Spotify and Full Truck Alliance.”
Thermo Fisher Scientific - June 2026
Listed in Harding Loevner Global Equity’s reported holdings.
Thermo Fisher Scientific - June 2026
“We added to the portfolio’s holdings in Intuit, Lowe’s, Medtronic, Meta (Facebook), Nike, PepsiCo, TE Connectivity, Thermo Fisher Scientific, and Tyson Foods.”
Thermo Fisher Scientific - June 2026
Listed in Artisan Partners Value Equity Strategy’s reported holdings.
Thermo Fisher Scientific - June 2026
Listed in Baron Health Care Fund’s reported holdings.
Thermo Fisher Scientific - New positionClearBridge Investments Value StrategyJune 2026
“In addition to the transactions discussed above, we initiated new positions in Vulcan Materials in the materials sector, TGS in the energy sector, FedEx Freight in the industrials sector, Brookfield Infrastructure in the utilities sector and Thermo Fisher Scientific in the health care sector.”
Thermo Fisher Scientific - June 2026
“Recent Activity During the second quarter, we initiated a new position in the aerospace and defense focused proprietary component manufacturer, Arxis . We took advantage of market volatility to add to our electrical systems and components designer and manufacturer, Amphenol , and also continued building our recently initiated position in the semiconductor equipment manufacturer, Lam Research. To finance these purchases, we exited two investments: Thermo Fisher Scientific , and Intuit , and reduced nine existing positions.”
Thermo Fisher Scientific - June 2026
“Recent Activity During the second quarter, we initiated a new position in the aerospace and defense focused proprietary component manufacturer, Arxis. We took advantage of market volatility to add to our electrical systems and components designer and manufacturer, Amphenol, and also continued building our recently initiated position in the semiconductor equipment manufacturer, Lam Research. To finance these purchases, we exited two investments: Thermo Fisher Scientific, and Intuit, and reduced nine existing positions.”
Thermo Fisher Scientific - June 2026
“We redeployed the proceeds into long-term compounders penalized by market anxiety—including adding to our existing positions of Amazon and Thermo Fisher Scientific.”
Thermo Fisher Scientific - New positionLiontrust Global Innovation FundJune 2026
Listed in Liontrust Global Innovation Fund’s reported holdings.
Thermo Fisher Scientific - June 2026
“We added materially to existing holdings on the same logic: Apple’s share count rose c.90% (now the Fund’s largest position at 5.4%), Danaher, Thermo Fisher, L’Oréal and Ferrari were all more than doubled, and Lilly, Amazon, Alphabet and Meta increased.”
Thermo Fisher Scientific - New positionLiontrust GF Global Innovation FundJune 2026
Listed in Liontrust GF Global Innovation Fund’s reported holdings.
Thermo Fisher Scientific - June 2026
“We added materially to existing holdings on the same logic: Apple’s share count rose c.90% (now the Fund’s largest position at 5.4%), Danaher, Thermo Fisher, L’Oréal and Ferrari were all more than doubled, and Lilly, Amazon, Alphabet and Meta increased.”
Thermo Fisher Scientific - June 2026
“Trading Activity 2Q During the quarter we added to the Fund’s positions in Danaher, Thermo Fisher Scientific, and Martin Marietta Materials at prices we think offer substantial upside with favorable risk profiles.”
Thermo Fisher Scientific - June 2026
“Portfolio activity beyond the entries and exits above was more muted and tilted toward trims. Beyond the exits of Accenture and Salesforce, we also trimmed our holdings of Alphabet, Amazon, Bio-Techne, SiriusXM and Thermo Fisher, partially offset by additions to Danaher and Global Payments.”
Thermo Fisher Scientific - June 2026
“Thermo Fisher Scientific (TMO), Moody’s (MCO), & Sherwin-Williams (SHW) We also exited our positions in Thermo Fisher Scientific, Moody’s, and Sherwin-Williams.”
Thermo Fisher Scientific - New positionKavaljer InvestmentbolagsfondMay 2026
“New positions are Alphabet and Thermo Fisher.”
Thermo Fisher Scientific - December 2025
“Positioning for uncertainty and leaning into technology adopters While equities finished out 2025 with gains, the quarter and full year were marked by considerable periods of volatility. With continued risk of turbulence in the market, we have been tilting the portfolio toward a more defensive positioning while taking offensive positions in areas where our convictions are highest. Within our offensive positioning, we have taken advantage of market volatility to lean into secular trends through investing in AI beneficiaries including hyperscalers, semiconductors and attractive areas of software, which we view as an “anti-bubble” strategy. The portfolio’s largest absolute sector weight continues to be Information Technology, although we reduced our overweight to the Tech sector given the stocks’ outperformance. We added one new position during the quarter, the home- goods retailer Home Depot in Consumer Discretionary. While the company has long been the dominant player in its space, the stock experienced a bout of underperformance in recent periods in a weak housing market. However, we viewed the entry price as fairly attractive in relation to what we consider durable secular trends around aging in place and an eventual housing recovery in the next year and a half. We exited Financials holding Fiserv after the company underwent a change in management and reset its earnings algorithm. We continue to view AI as a generational demand driver, creating a durable need for faster, more powerful and energy-efficient computing. We are also leaning into “adopters” of technology that are poised for U.S. exceptionalism, such as Eli Lilly and Boston Scientific, that continue to innovate to improve patient outcomes. We favor life science tools companies such as Danaher and Thermo Fisher, which provide valuable equipment and services for clinical research.”
Thermo Fisher Scientific - December 2025
“GLP-1 maker Eli Lilly, Argenx and Vertex Pharmaceuticals were bright spots in the biopharmaceutical segment of health care while diagnostics supplier Thermo Fisher Scientific benefited from stabilizing R&D spending.”
Thermo Fisher Scientific - New positionBroyhill Asset ManagementDecember 2025
“Consequently, we cut the position in half after the company announced management changes and second-quarter results that again fell short of our expectations, and reinvested the proceeds into Thermo Fisher, the primary beneficiary of Avantor’s challenges.”
Thermo Fisher Scientific - September 2025
“Despite these headwinds, the Strategy saw bright spots in the quarter with managed care provider UnitedHealth stabilizing and life sciences tools company Thermo Fisher Scientific seeing strong momentum from pharma and biotech customers.”
Thermo Fisher Scientific - August 2025
“we have used the proceeds to help build up our two most recent additions, Thermo Fisher and CPKC, which we believe may offer superior return potential compared to Hershey.”
Thermo Fisher Scientific - HoldsFederated Hermes Sustainable Global EquityJune 2025
“The Strategy returned -2.72% in USD terms on a relative basis – underperforming its benchmark, the MSCI ACWI, over the first six months of 2025. Q1 2025 was a challenging period for the Strategy, particularly as shifts in sentiment and doubts around US tech led to underperformance from previous top performers such as Nvidia, TSMC and Microsoft. Performance improved in Q2, and the Strategy ended the quarter broadly in line with the benchmark. Outperformance in April and May was driven by the Strategy’s quality bias, which proved advantageous amid elevated market volatility and uncertainty. In contrast, June proved more challenging as a shift towards risk-on sentiment saw many quality-oriented and defensive names trailing. Outperformance in April and May was driven by the Strategy’s quality bias, which proved advantageous amid elevated market volatility and uncertainty. stagnant GDP environment. This was further supported by an improving macro backdrop, including rising wages, increased small and medium-sized enterprise (SME) lending, and easing concerns around tariffs. RELX’s shares gained after the company issued positive Q1 sales guidance, announcing that the year had started well across all four business areas. The company’s improving long-term growth trajectory continues to be driven by the ongoing shift towards higher growth analytics and decision tools. Thermo Fisher, Gartner and Novo Nordisk detracted the most from performance. Thermo Fisher shares were impacted by concerns over US policy and tariffs, though the company remains well-positioned for long-term structural trends in healthcare.”
Thermo Fisher Scientific
Also mentioned · 3
These funds discuss Thermo Fisher Scientific as a competitor, benchmark or comparable, without disclosing a position in it.
- MentionedGeneration IM Global Equity StrategyJuly 2026
“In our base case we model around 8% revenue and 16% unlevered earnings growth annually over the next five years. We are impressed with West’s management team, which receives a 2 on our rating of Management Quality. This August the company will appoint only its seventh chief executive in more than a century – testament to the long-term culture of the business. The incoming CEO, Michel Lagarde of Thermo Fisher Scientific, is a serious hire.”
Thermo Fisher Scientific - MentionedBroyhill AMMarch 2026
“Avantor made our list of detractors for the last time in the first quarter. The destocking cycle has run far longer than we initially modeled, but the bigger issue was self-inflicted. Successive management teams failed to defend the share against Thermo Fisher.”
Thermo Fisher Scientific - MentionedDavis Global FundJune 2025
“Solventum Solventum is a U.S. healthcare business spun out of 3M in April 2024. The company generated over $8 billion in revenue in 2024, most of which came from selling medical-surgical products (mostly for infection prevention and wound care) to hospitals and clinics. Solventum also sells products to dentist offices (e.g., consumables for preventive dental care) as well as coding and transcribing software to hospitals. The business has a long history of attractive growth and margins, but performance weakened under 3M ownership in recent years due to a lack of new product investment and poor integration of acquired businesses, among other factors. The management team, led by industry veteran Bryan Hanson, has deep healthcare experience and a successful collaboration under their belts at a prior healthcare spinoff (Covidien). They are highly focused on reinvigorating earnings growth (back to approximately 4–5% annually) and growing margins. They have also approached the portfolio with fresh eyes, which led to an agreement to sell a non-core purification and filtration business to Thermo Fisher Scientific for an attractive price.”
Thermo Fisher Scientific
Fund coverage · 10 theses
- Broyhill Equity CompositeSeptember 2026
Thermo Fisher Scientific is benefiting from broad-based demand recovery and management’s raised guidance.
Read the full thesis - Baron Health Care FundSeptember 2026
Thermo Fisher Scientific Inc. is a life sciences tools company with scale, disciplined capital allocation, and margin expansion positioned to lead an उद्योग recovery.
Read the full thesis - Lindsell Train Global Equity FundSeptember 2026
Thermo Fisher Scientific is positioned as a beneficiary of broad biotech and pharma demand as well as AI-driven process efficiencies.
Read the full thesis - Kavaljer InvestmentbolagsfondSeptember 2026
Thermo Fisher Scientific is positioned to benefit from recovering volumes, AI-driven lab investment, and operating leverage across its broad life-science platform.
Read the full thesis - Buffalo Growth FundSeptember 2026
Thermo Fisher Scientific, a life sciences tools provider, has turned a corner with stabilizing China and academic/government markets and improving pharma and biotech spending.
Read the full thesis - Baron Health Care FundDecember 2025
Thermo Fisher Scientific Inc. is a dominant life science tools company with improving end markets and a path to accelerating organic and earnings growth.
Read the full thesis - Baron Health Care FundSeptember 2025
Thermo Fisher Scientific Inc. is a competitively advantaged life sciences tools company poised for accelerated growth, expecting 3%-6% organic revenue growth in 2026-2027 and over 7% beyond, following a challenging period.
Read the full thesis - Loomis Sayles Growth FundJune 2025
Thermo Fisher Scientific (TMO) is well-positioned for long-term growth in the life sciences tools industry, with a strong focus on biopharma, anticipated high-single-digit revenue growth, and undervalued share price offering a compelling investment opportunity despite current market pessimism.
Read the full thesis - Artisan Value Equity StrategyJune 2025
Thermo Fisher Scientific (TMO) is a leading life science tools company with strong growth potential in fast-growing markets, solid financials, and a largely recurring revenue model, making it an attractive investment despite current market challenges.
Read the full thesis - Lindsell Train North American Equity FundDecember 2024
Thermo Fischer is a leading global life sciences tools and diagnostics company that benefits from industry growth and recurring revenues, making it an attractive investment opportunity despite recent flat share performance.
Read the full thesis
Read every full thesis on Thermo Fisher Scientific
Read all 10 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→Share this ledger